Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
North Memorial Medical Health Center
mi
from
Robbinsdale, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
North Memorial Medical Health Center
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Park Nicollet Clinic - Saint Louis Park
mi
from
Saint Louis Park, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Park Nicollet Clinic - Saint Louis Park
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Regions Hospital
mi
from
Saint Paul, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Regions Hospital
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
United Hospital
mi
from
Saint Paul, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
United Hospital
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Saint Francis Regional Medical Center
mi
from
Shakopee, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Saint Francis Regional Medical Center
mi
from
Shakopee, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Ridgeview Medical Center
mi
from
Waconia, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Ridgeview Medical Center
mi
from
Waconia, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Minnesota Oncology Hematology PA-Maplewood
mi
from
Maplewood, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Minnesota Oncology Hematology PA-Maplewood
mi
from
Maplewood, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Hennepin County Medical Center
mi
from
Minneapolis, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
The Mayo Clinic
mi
from
Rochester, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Metro Minnesota Community Oncology Research Consortium
mi
from
Saint Louis Park, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Metro Minnesota Community Oncology Research Consortium
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Minnesota Oncology and Hematology PA-Woodbury
mi
from
Woodbury, MN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Minnesota Oncology and Hematology PA-Woodbury
mi
from
Woodbury, MN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
Wisconsin Clinical Cancer Center
mi
from
Milwaukee, WI
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
Wisconsin Clinical Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  4/11/2016
University Health Network-Princess Margaret Hospital
mi
from
Toronto,
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 4/11/2016
University Health Network-Princess Margaret Hospital
mi
from
Toronto,
Click here to add this to my saved trials
A Study of PNT2258 in Patients With Advanced Solid Tumors
A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  4/11/2016
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
A Study of PNT2258 in Patients With Advanced Solid Tumors
A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 4/11/2016
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Tucson, AZ
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Aurora, CO
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Atlanta, GA
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Chicago, IL
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
St Louis, MO
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Omaha, NE
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Lebanon, NH
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Portland, OR
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Bethlehem, PA
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Greenville, SC
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Dallas, TX
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
San Antonio, TX
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Madison, WI
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  4/12/2016
mi
from
Hamilton,
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 4/12/2016
mi
from
Hamilton,
Click here to add this to my saved trials
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma
Status: Enrolling
Updated:  4/15/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma
Status: Enrolling
Updated: 4/15/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
A Pilot Study of the Combination of Nab-paclitaxel, Temozolomide and Bevacizumab in Patients With Metastatic Melanoma With Brain Metastases
Status: Enrolling
Updated:  4/20/2016
University of Arizona Cancer Center
mi
from
Tucson, AZ
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
A Pilot Study of the Combination of Nab-paclitaxel, Temozolomide and Bevacizumab in Patients With Metastatic Melanoma With Brain Metastases
Status: Enrolling
Updated: 4/20/2016
University of Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
A Pilot Study of the Combination of Nab-paclitaxel, Temozolomide and Bevacizumab in Patients With Metastatic Melanoma With Brain Metastases
Status: Enrolling
Updated:  4/20/2016
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
A Pilot Study of the Combination of Nab-paclitaxel, Temozolomide and Bevacizumab in Patients With Metastatic Melanoma With Brain Metastases
Status: Enrolling
Updated: 4/20/2016
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study to Document the Effect of Petrolatum on Innate Immune Responses in the Skin
A Study to Document the Effect of Petrolatum on Innate Immune Responses in the Skin
Status: Enrolling
Updated:  4/26/2016
Rockefeller University
mi
from
New York, NY
A Study to Document the Effect of Petrolatum on Innate Immune Responses in the Skin
A Study to Document the Effect of Petrolatum on Innate Immune Responses in the Skin
Status: Enrolling
Updated: 4/26/2016
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated:  5/2/2016
Cedars Sinai Medical Center SC - 4
mi
from
Los Angeles, CA
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated: 5/2/2016
Cedars Sinai Medical Center SC - 4
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated:  5/2/2016
Stanford University Medical Center Stanford Cancer Center (3)
mi
from
Stanford, CA
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated: 5/2/2016
Stanford University Medical Center Stanford Cancer Center (3)
mi
from
Stanford, CA
Click here to add this to my saved trials
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated:  5/2/2016
H. Lee Moffitt Cancer Center & Research Institute Dept.of H.LeeMoffittCC&RI(1)
mi
from
Tampa, FL
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated: 5/2/2016
H. Lee Moffitt Cancer Center & Research Institute Dept.of H.LeeMoffittCC&RI(1)
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated:  5/2/2016
University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology
mi
from
Houston, TX
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated: 5/2/2016
University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology
mi
from
Houston, TX
Click here to add this to my saved trials